UCLA Discovers First Drug to Replicate Stroke Rehabilitation Effects in Mice

The Gap in Stroke Treatment

Stroke is the leading cause of adult disability, yet no recovery drug exists. Physical rehabilitation remains the only standard treatment - limited in effectiveness and hard for most patients to sustain at the necessary intensity.

The Discovery

A UCLA Health research team led by Dr. S. Thomas Carmichael identified that stroke damages brain connections far beyond the site of injury. Specifically, it disrupts parvalbumin neurons - cells critical for maintaining brain rhythm - in remote brain areas.

The team developed two candidate drugs targeting this mechanism. DDL-920, developed in Dr. Varghese John's lab, produced significant recovery in movement control after stroke in mice - the first drug to achieve what physical rehabilitation achieves.

Why This Matters

Published in Nature Communications, this research opens a path toward a stroke recovery drug patients could take at home. It doesn't eliminate the need for rehabilitation, but pharmacological support could dramatically improve outcomes for the majority of stroke patients who can't access intensive therapy. Clinical trials in humans are the next step.